UTP18

Across TCGA pan-cancer cohorts, UTP18 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UTP18 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher UTP18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UTP18 expression acts as an unfavorable survival marker.

ACC, LUSC, and SKCM are the cancer types where UTP18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LUSC	OS	Median	II,III,IV	0.002	0.743	<.001	12	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UTP18–ACC (DFS)

Open the ACC breakdown →